Search

everythinglearnresearchcommunity

for

Search:↓

Concerns about CosmeRNA safety mechanisms and potential side effects. Discussion includes comparisons to Fluridil and questions about nanoparticle specificity and siRNA stability.

A user is upset about hair loss due to seborrheic dermatitis and DUPA, which prevents a hair transplant. They mention using jojoba oil and discuss treatments like Minoxidil, finasteride, and RU58841.

The user has been on finasteride for over two years, experiencing early hair regrowth, acne, and scalp sensitivity, but now faces thinning hair and questions about dosage and long-term effectiveness. They also used retinal to help with acne and are seeking advice on whether to adjust their finasteride dose.

The conversation discusses using TH16, a topical melatonin with resveratrol, and stemoxydine for hair maintenance, avoiding finasteride and minoxidil due to side effects. The user is considering a low-dose topical finasteride despite sensitivity.

The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.

Increased Malassezia and Cutibacterium in the scalp microbiome are linked to higher sebum production and inflammation in androgenetic alopecia (AGA). Treatments include ciclopirox shampoo, benzoyl peroxide shampoo, clobetasol propionate, calcipotriol, minoxidil, finasteride, and dutasteride.

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

The emotional impact of hair loss and the risks associated with common treatments such as finasteride, dutasteride, minoxidil, RU58841, and Fluridil. People discussed their personal experiences with these treatments, including potential side effects and lowered fertility. Hair transplants were also mentioned as a possible solution.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

A user's 14-month journey with finasteride, microneedling, and Nizoral to treat hair loss. They experienced some side effects such as ball ache, needing to pee constantly, and less semen, but the results were generally positive.

A new hair loss treatment, PP405, is moving from phase 2A to 2B in clinical trials, sparking discussions about its potential to regrow dormant hairs and its impact on existing treatments like Minoxidil and finasteride. Some users express skepticism, while others are hopeful about its future effectiveness.

A 31-year-old with diffuse thinning experienced significant hair regrowth after nearly 5 months on Finasteride 0.75mg MWF. Despite initial side effects like testicle pain and reduced sex drive, these issues resolved, and positive effects included reduced nighttime urination and scalp itching.

Amplifica's new injectable treatment for androgenetic alopecia shows a 15% increase in hair thickness and coarseness in 60 days. The treatment is in early human trials and offers a promising alternative to hormone-related hair loss treatments.

A person considering finasteride for hair loss checked their hormone levels before starting treatment. They are concerned about the potential increase in estradiol and its effects, as well as the impact on their sex hormone-binding globulin (SHBG) and free testosterone levels.

A user is concerned about the impact of topical dutasteride on sperm quality and potential long-term fertility issues. They are using microneedling with a 0.025% dutasteride solution and are seeking information on whether sperm parameters return to normal after stopping the drug.

Finasteride and dutasteride, used for hair loss, can cause sexual dysfunction, depression, and suicidal thoughts, with some effects persisting after stopping. The post stresses the importance of being aware of these risks.

User shared a 1-year update on finasteride, noting thicker hair but mild side effects like reduced libido and mild ED. Considering reducing the dose from 1mg to 0.5mg daily to alleviate side effects.

A 57-year-old man with male pattern hair loss and insulin resistance experienced hair regrowth and weight loss after using tirzepatide, without other hair treatments. Dysregulated glucose metabolism is linked to hair loss, with tirzepatide potentially improving hair density by normalizing insulin resistance.

The conversation discusses scalp itching and tenderness after microneedling, despite using medicated shampoos and proper sanitation. The user plans to see a dermatologist and is concerned about possible infection or allergic reaction.

The user is experiencing sudden hair loss and is considering micro-needling, low-level light therapy, iron supplements, folihair, and Omega 3. They are hesitant to start finasteride, suspecting the hair loss might be due to telogen effluvium from a past COVID-19 infection.

PP405 shows potential for hair growth, with 31% of advanced balding men experiencing over 20% increase in hair density in 8 weeks. However, skepticism persists due to selective data presentation and lack of long-term results, with comparisons to treatments like minoxidil and finasteride.

Long-term use of dutasteride may impair semen volume and sperm motility, but these effects are often reversible after stopping the drug. Individual reactions vary, and more research is needed to understand the long-term impact on fertility.

Clascoterone (CB) shows an excellent safety profile with no serious side effects, but its effectiveness may decline after six months, making it more suitable as an adjunct treatment with finasteride and minoxidil rather than a standalone solution. Some argue it could be better than finasteride due to its protection against testosterone, but its long-term efficacy remains debated.

The conversation discusses the side effects of finasteride, including low libido and erectile dysfunction, and the possibility of these effects being permanent, known as post-finasteride syndrome (PFS). Some users report personal experiences with PFS and debate whether the condition is real, with varying opinions on the reversibility of side effects and the role of individual biology.

Dutasteride is more effective than finasteride, has neuroprotective benefits, and may prevent acne. Despite initial concerns about metabolic effects, further research suggests it is safe for most users, especially if not hypogonadal.

The user experienced hairline improvement using microneedling once a month with a 12-pin set at 1.5-2.0mm and taking Tru Niagen, alongside a heavily modified diet. They attribute the slow hairline improvement to environmental factors, particularly diet, rather than solely genetic factors.

PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.

The conversation discusses hair loss treatments, focusing on the use of Minoxidil, finasteride, and triamcinolone. Concerns are raised about high concentrations of Minoxidil and the long-term use of corticosteroids.

PP405 shows promise in treating severe hair loss, with 31% of users experiencing over 20% hair density increase in four weeks, faster than minoxidil and finasteride. Some users are skeptical about the results' significance and long-term efficacy.

A medical student experienced hair loss slowing with Finasteride but developed severe, treatment-resistant insomnia. They tried various medications with little effect, suspecting Post-Finasteride Syndrome, and others suggested the insomnia might be linked to Finasteride's impact on neurosteroids.